Skip to main content

Table 5 Clinical characteristics associated with EQ-5D and EQ-VAS score of patients with HIV/AIDS, TASH, Ethiopia, 2019 (n = 511)

From: Health-related quality of life of patients with HIV/AIDS at a tertiary care teaching hospital in Ethiopia

Patient character EQ-5D EQ-VAS
Median [IQR] Mean rank p value Median [IQR] Mean rank p value
CD4 cells/mm3
 > 500 1 [0.94–1] 339  < 0.001* 90 [82–99.75] 346  < 0.001*
[350–500] 0.94 [0.88–1] 258 85 [70.25–90] 268
[200–350] 0.94 [0.86–0.97] 232 77.5 [65–85] 213
[100–200] 0.88 [0.76–0.95] 172 70 [60–85] 184
 < 100 0.88 [0.66–0.96] 184 60 [50–83.75] 166
WHO clinical stage at diagnosis
I 0.94 [0.85–0.97] 233 0.06 85 [72.5–90] 264 0.08
II 0.96 [0.87–1] 261 85 [70–95] 266
III 0.96 [0.89–1] 273 82.5 [70–95] 265
IV 0.94 [0.86–1] 235 80 [65–90] 229
Viral load
 < 50 copies/ml 0.95 [0.88–1] 263 0.005* 85 [70–95] 267  < 0.001*
51–1000 copies/ml 0.94 [0.88–1] 257 82.5 [70–95] 260
 > 1000 copies/ml 0.88 [0.7–0.98] 196 70 [60–80] 169
Type of medicine
AZT/3TC/EFV 0.97 [0.94–1] 309 0.004* 82.5 [70–91.75] 286 0.002*
AZT/3TC/NVP 0.96 [0.88–1] 271 85 [71.25–90] 278
TDF/3TC/EFV 0.96 [0.88–1] 264 85 [70–95] 268
TDF/3TC/NVP 0.94 [0.89–1] 269 85 [75–95] 280
ABC + 3TC + EFV 0.88 [0.82–0.96] 189 70 [60–80] 192
TDF + 3TC + ATV/r 0.82 [0.77–0.97] 253 70 [51.25–85] 238
Others** 0.94 [0.86–1] 205 80 [65–90] 193  
Number of medicine
1 0.96 [0.9–1] 289  < 0.001* 90 [70–95] 289  < 0.001*
2 0.94 [0.85–0.97] 240 80 [70–90] 246
3 0.94 [0.86–1] 239 80 [65–90] 240
4 0.91 [0.83–0.97] 225 75 [60–90] 214
 > 4 0.89 [0.76–0.97] 179 70 [50–80] 144
Duration of treatment  
 < 1 year 0.96 [0.94–0.96] 49 0.08 85 [72.5–90] 51 0.12
1–5 years 0.92 [0.86–0.97] 50 80 [66.25–90] 45
 > 5 years 0.96 [0.88–1] 51 82.5 [70–95] 55
Adherence
Good 0.95 [0.88–1] 259 0.14 80 [70–90] 259 0.08
Fair 0.93 [0.84–1] 225 72.5 [56–93.75] 223
Poor 0.89 [0.7–1] 209 70 [60–90] 201
History of treatment failure
Yes 0.92 [0.83–0.97] 210 0.001* 70 [60–85] 195  < 0.001*
No 0.96 [0.88–1] 266 85 [70–95] 270
Comorbidities
No 0.96 [0.88–1] 216 0.001* 85 [70–95] 213  < 0.001*
OIs 0.92 [0.84–0.97] 273 70 [55–90] 274
Non-OIs 0.92 [0.8–0.97] 336 80 [65–90] 237
  1. *Significant value
  2. **Others: ABC + 3TC + NVP, TDF + 3TC + LPV/r and AZT + 3TC + LPV/r; NVP: Nevirapine; ABC: Abacavir; OIs: Opportunistic infect